UM: Targeting CARM1 Inhibits AML and Spares Normal Cells

UM: Targeting CARM1 Inhibits AML and Spares Normal Cells

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that inhibiting the enzyme CARM1 (also called PRMT4) dramatically slows acute myeloid leukemia (AML) progression but does not affect normal blood production.

Full Story

Related posts

Stanford, UCF Study Finds People Avoid Virtual Humans in Real World

Interacting with virtual humans in an augmented reality training environment seems to carry over into…

UM New Study Identifies Molecular Aging ‘Midlife Crisis’

Just as a computer requires code to work, our bodies are regulated by molecular “programs”…

FIU Researchers agree: Brain health is about more than just age, genetics

According to the Alzheimer’s Association, more than 50 million individuals are currently living with dementia.…